Drugs / XB628
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06952010 | May 2025 → May 2027 expected | cancer, metastatic neoplasm | Exelixis | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | Exelixis | Results Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 exelixis.com ↗
Data from this analysis show that XB628 is efficacious in tumor cell killing in vitro and in vivo, supporting advancement of this molecule into clinical development. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | Exelixis | Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 exelixis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XB628 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06952010 ↗ |
| Route | Intravenous | “Intravenous infusion(s)” NCT06952010 ↗ |